| The Star Entertainment Group Limited (SGR) ORDINARY FULLY PAID |
Consumer Discretionary |
$863 |
Quarterly Activities & Appendix 4C Cash Flow Report
|
28 Apr 2026 9:23AM |
$0.115 |
$0.130 |
risen by
13.04%
|
|
SGR - Price-sensitive ASX Announcement
Full Release
Key Points
- Q3 FY26 revenue was $266 million, down 12% from Q2 FY26.
- EBITDA loss for Q3 FY26 was $1 million, a 96% reduction compared to Q3 FY25.
- The Star entered a refinancing agreement with WhiteHawk to refinance existing debt.
- Available cash as of 31 March 2026 was $90 million.
- Cost-saving initiatives are underway, including corporate office streamlining.
- The Star's casino licenses faced regulatory updates, with some suspensions extended.
- The JVP Transaction's first stage was completed, exiting the Destination Brisbane Consortium.
- Payments to related parties totaled $3.9 million for operating activities.
- Mandatory carded play and cash limit regulations were implemented in The Star Sydney.
- The Star's future operations depend on resolving material uncertainties.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Stellar Resources Limited (SRZ) ORDINARY FULLY PAID |
Materials |
$134 |
High Grade Tungsten and Silver at Scamander
|
28 Apr 2026 9:22AM |
$0.034 |
$0.395 |
risen by
1,079.10%
|
|
SRZ - Price-sensitive ASX Announcement
Full Release
Key Points
- High-grade tungsten results at Lutwyche with best sample at 6.9% WO3.
- Carson De Beers prospect shows high historical tungsten results of up to 8.3% WO3.
- Scamander Bell site showed extreme silver grades, some over 1000g/t Ag.
- New high-grade polymetallic discovery at North Scamander with significant silver and other minerals.
- Stellar plans systematic exploration including soil surveys, geophysics, and scout drilling.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Karoon Energy Ltd (KAR) ORDINARY FULLY PAID |
Energy |
$1,218 |
2026 First Quarter results
|
28 Apr 2026 9:22AM |
$2.180 |
$1.745 |
fallen by
19.95%
|
|
KAR - Price-sensitive ASX Announcement
Full Release
Key Points
- Karoon Energy Ltd experienced a decrease in production and sales in Q1 2026 due to maintenance and a riser issue.
- The company generated US$128.2 million in sales revenue, reflecting improved oil prices but lower production volumes.
- Baúna FPSO's transition to Karoon operatorship is expected by mid-2026, improving control and efficiency.
- Karoon's net debt was US$180.6 million with liquidity at US$452.7 million at the end of Q1 2026.
- Karoon anticipates higher free cash flow in the second half of 2026 as production increases and capital outflows decrease.
- Capital expenditure increased due to additional drilling at Who Dat, with guidance adjusted accordingly.
- The company is evaluating the impact of Brazil's temporary export tax on crude oil sales.
- The first quarter was marked by significant oil price volatility due to geopolitical tensions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Chilwa Minerals Ltd (CHW) ORDINARY FULLY PAID |
Materials |
$69 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Apr 2026 9:21AM |
$0.940 |
$0.700 |
fallen by
25.53%
|
|
CHW - Price-sensitive ASX Announcement
Full Release
Key Points
- Niobium discovery confirmed at Nakombe target, Mpyupyu area.
- Diamond drilling operational with two rigs deployed.
- Significant mineralization includes niobium, tantalum, and gallium.
- Resource definition drilling completed at Northern Shore deposits.
- Company is progressing with a Scoping Study for heavy mineral sands.
- Proposed NASDAQ listing and initiated equity research coverage.
- Chilwa holds a strong cash position with $3.57 million.
- Engagement with US Government officials and ongoing community efforts.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| C29 Metals Limited (C29) ORDINARY FULLY PAID |
Materials |
$4 |
Trading Halt
|
28 Apr 2026 9:21AM |
$0.032 |
$0.016 |
fallen by
50%
|
|
C29 - Price-sensitive ASX Announcement
Full Release
Key Points
- C29 Metals Limited requested a trading halt on its securities.
- The trading halt is due to a material acquisition and capital raising announcement.
- The halt will last until the announcement is made, expected by the market pre-open on 30 April 2026.
- ASX Listing Rule 17.1 was referenced for the trading halt procedure.
- The company is unaware of any reason the trading halt should not be granted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Australian Mines Limited (AUZ) ORDINARY FULLY PAID |
Materials |
$68 |
Join Our Flemington Scoping Study Webinar
|
28 Apr 2026 9:21AM |
$0.019 |
$0.031 |
risen by
67.57%
|
|
| Energy Resources of Australia Limited (ERA) ORDINARY FULLY PAID 'A' |
Energy |
$811 |
Appendix 3Y - Justin Carey
|
28 Apr 2026 9:20AM |
$0.004 |
$0.002 |
fallen by
42.86%
|
|
| Dimerix Limited (DXB) ORDINARY FULLY PAID |
Health Care |
$165 |
ACTION3 Statistical Review Complete
|
28 Apr 2026 9:20AM |
$0.390 |
$0.275 |
fallen by
29.49%
|
|
DXB - Price-sensitive ASX Announcement
Full Release
Key Points
- An external statistical blinded review of ACTION3 data confirmed the study's statistical power is over 90% to demonstrate a treatment effect for proteinuria.
- Dimerix continues the ACTION3 Phase 3 study to the final proteinuria endpoint to increase chances of regulatory success.
- FDA agreed that proteinuria is an appropriate endpoint for full regulatory approval of DMX-200 in ACTION3.
- Recruitment for pediatric patients remains ongoing, potentially allowing expansion to adolescents.
- ACTION3 Phase 3 study passed a formal futility analysis in March 2024, showing better performance than placebo.
- Proteinuria is confirmed as the primary endpoint, which is statistically more achievable than eGFR endpoints.
- Dimerix decided against pursuing an interim analysis for accelerated approval due to added costs and risks.
- The study aims for traditional approval through the 505(b)(1) pathway with proteinuria as the primary endpoint and eGFR as a secondary endpoint.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Centaurus Metals Limited (CTM) ORDINARY FULLY PAID |
Materials |
$318 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Apr 2026 9:19AM |
$0.640 |
$0.560 |
fallen by
12.50%
|
|
CTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Centaurus Metals Limited reported a net cash outflow from operating activities of A$2,229,000 for the quarter.
- Cash used in investing activities was A$1,918,000, primarily for property, plant and equipment.
- The company raised A$1,119,000 from the exercise of options in financing activities.
- At the end of the quarter, Centaurus Metals had cash reserves of A$21.6 million.
- Significant interest was received from international financiers, including a Letter of Intent from BNDES for US$190 million.
- A foundational Offtake Agreement with Glencore AG was executed for high-grade nickel concentrate.
- A pilot plant test work program at the Jambreiro Iron Ore Project produced high-quality direct reduction pellet feed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| VBX Limited (VBX) ORDINARY FULLY PAID |
Materials |
$38 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
28 Apr 2026 9:19AM |
$0.660 |
$0.890 |
risen by
34.85%
|
|
VBX - Price-sensitive ASX Announcement
Full Release
Key Points
- VBX Limited reported its Quarterly Activities and Cash Flow Report for the period ending 31 March 2026.
- The Wuudagu bauxite project is a key focus, with significant progress in resource estimation and feasibility studies.
- Net cash used in operating activities was $2,694,000 for the current quarter and $10,555,000 for the nine months ended 31 March 2026.
- Cash used in investing activities was negligible, with a total of $12,000 spent over the nine months.
- Financing activities saw a net inflow of $1,500,000 for the quarter, primarily from new borrowings.
- Cash and cash equivalents at the end of the period were $398,000, down from $1,592,000 at the start of the quarter.
- Payments to related parties amounted to $28,000 for the quarter.
- The Wuudagu project aims to produce high-grade, low-silica bauxite.
- Metallurgical tests indicate the potential for high-quality bauxite production using beneficiation methods.
- VBX is engaging in discussions for project funding and offtake agreements.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| EQ Resources Limited (EQR) ORDINARY FULLY PAID |
Materials |
$2,115 |
Quarterly Activities/Appendix 5B Cash Flow Report-March 2026
|
28 Apr 2026 9:19AM |
$0.290 |
$0.410 |
risen by
41.38%
|
|
EQR - Price-sensitive ASX Announcement
Full Release
Key Points
- Net cash outflow from operating activities of A$11.5 million.
- Net cash inflow from financing activities of A$10 million.
- Exploration and development at Mt Carbine and Barruecopardo.
- Strong tungsten market performance due to supply constraints and geopolitical factors.
- Commitment to sustainability and ESG initiatives.
- Expansion of corporate capabilities with new office lease in Brisbane.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| iCetana Limited (ICE) ORDINARY FULLY PAID |
Information Technology |
$23 |
Trading Halt
|
28 Apr 2026 9:18AM |
$0.035 |
$0.035 |
fallen by
0%
|
|
ICE - Price-sensitive ASX Announcement
Full Release
Key Points
- icetana Limited requests trading halt on ASX
- Trading halt pending announcement of capital raising
- Halt effective immediately as per ASX Listing Rule 17.1
- Halt to remain until announcement or trading on 30 April 2026
- Company sees no reason for halt request to be denied
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Energy Resources of Australia Limited (ERA) ORDINARY FULLY PAID 'A' |
Energy |
$811 |
Appendix 3Y - Rosemary Fagen
|
28 Apr 2026 9:17AM |
$0.004 |
$0.002 |
fallen by
42.86%
|
|
| 6K Additive, Inc (6KA) CDI 1:1 US PERSON PROHIBITED EXCLUDING QIB |
Materials |
$155 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Apr 2026 9:17AM |
$0.778 |
$0.890 |
risen by
14.47%
|
|
6KA - Price-sensitive ASX Announcement
Full Release
Key Points
- Island Pharmaceuticals Limited focuses on urgent viral diseases and biosecurity threats.
- They are developing ISLA-101 and Galidesivir as part of their strategy.
- ISLA-101 is used for dengue fever prevention and treatment.
- Galidesivir is an antiviral molecule targeting multiple RNA viruses.
- The company held $14.18 million in cash as of March 2026.
- Net cash used in operations was $1.3 million for the quarter.
- Payments to related parties totaled $139,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Beach Energy Limited (BPT) ORDINARY FULLY PAID |
Energy |
$1,962 |
FY26 Third Quarter Activities Report
|
28 Apr 2026 9:16AM |
$1.195 |
$0.860 |
fallen by
28.03%
|
|
BPT - Price-sensitive ASX Announcement
Full Release
Key Points
- Beach Energy's production increased by 7% to 4.8 MMboe quarter-on-quarter.
- Strong performance from the Waitsia Gas Plant, reaching 94% of nameplate capacity.
- Challenges included severe rains impacting production in Cooper Basin and Western Flank.
- Sales revenue stood at $419 million, a 6% decrease from the previous quarter.
- Average realised oil price rose by 19% to A$125 per barrel.
- Liquidity increased to $974 million, with net gearing reduced to 11%.
- Production guidance revised to 19.4 – 20.3 MMboe for FY26.
- Successful drilling campaigns were conducted, with 100% success in the Cooper Basin JV.
- Moomba Central Optimisation project aims to enhance infrastructure and production.
- New acreage awarded in the Taroom Trough and Cooper Basin for future exploration.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Ausquest Limited (AQD) ORDINARY FULLY PAID |
Materials |
$79 |
Quarterly Activities and Cashflow Report
|
28 Apr 2026 9:15AM |
$0.045 |
$0.048 |
risen by
6.67%
|
|
AQD - Price-sensitive ASX Announcement
Full Release
Key Points
- Cangallo Copper-Gold Project in Peru shows significant mineralization.
- Significant copper and gold grades confirmed in drilling results.
- Plans to commence diamond drilling and further RC drilling.
- Preparation for exploration activities in Australia, including Balladonia and Coober Pedy.
- Quarter-end cash position of $10.2 million.
- Funding includes contributions from South32 for Australian projects.
- Ongoing assessment of new opportunities within Australia.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Biome Australia Limited (BIO) ORDINARY FULLY PAID |
Consumer Staple |
$78 |
Quarterly Activities & Cashflow Report
|
28 Apr 2026 9:14AM |
$0.325 |
$0.340 |
risen by
4.62%
|
|
BIO - Price-sensitive ASX Announcement
Full Release
Key Points
- Activated Probiotics surpassed 1 million boxes sold.
- Biome is on track for 100 million doses delivered by Q4 FY26.
- Activated Probiotics is the fastest-growing probiotic brand in Australia.
- National campaign launched in Canada for Activated Probiotics.
- Net cash increase at bank for Q3 FY26 to $3,387k.
- BMB18 clinical trial to commence and patent application filed.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Red Mountain Mining Limited (RMX) ORDINARY FULLY PAID |
Materials |
$9 |
Trading Halt
|
28 Apr 2026 9:14AM |
$0.019 |
$0.009 |
fallen by
52.63%
|
|
RMX - Price-sensitive ASX Announcement
Full Release
Key Points
- Trading in Red Mountain Mining Limited (ASX: RMX) has been halted at RMX's request.
- The trading halt is due to a material agreement relating to a new Tungsten Project.
- RMX is planning, executing, and completing a capital raising.
- The halt will last until normal trading on Thursday, 30 April 2026, or until the announcement is released.
- The company is not aware of any reason why the trading halt should not be granted.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| 1414 Degrees Limited (14D) ORDINARY FULLY PAID |
Industrials |
$47 |
SiNTL Update - Drone & UAV Market Engagement to Commence
|
28 Apr 2026 9:14AM |
$0.018 |
$0.066 |
risen by
266.67%
|
|
14D - Price-sensitive ASX Announcement
Full Release
Key Points
- SiNTL outperforms traditional graphite and silicon batteries.
- SiNTL offers improved energy capacity, faster charging, and maintained cycle stability.
- 1414 Degrees is engaging with the drone and UAV market to utilize SiNTL.
- The drone market is forecasted to reach US$160 billion by 2030.
- SiNTL is designed for easy integration with existing battery manufacturing processes.
- Special aluminium coating on SiNTL anodes mitigates volume expansion.
- 1414 Degrees is advancing the SiNTL silicon nanoparticle anode program.
- SiNTL provides a lower-cost upgrade to graphite anodes.
- Focus on scale-up and manufacturing process optimization for SiNTL.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| European Lithium Limited (EUR) ORDINARY FULLY PAID |
Materials |
$656 |
EUR to combine with CRML implied valuation $0.58 per share
|
28 Apr 2026 9:14AM |
$0.285 |
$0.380 |
risen by
33.33%
|
|
EUR - Price-sensitive ASX Announcement
Full Release
Key Points
- European Lithium Limited (ASX: EUR) has entered into a non-binding indicative agreement with Critical Metals Corp (CRML).
- The proposal involves CRML acquiring 100% of European Lithium's issued securities via a scheme of arrangement for scrip consideration.
- Each EUR shareholder will receive CRML scrip valued at A$0.58 per EUR share held.
- The proposal offers a significant premium for EUR shareholders, representing a 137% premium over the last closing price.
- EUR shareholders are expected to own approximately 45% of the combined entity post-transaction.
- The transaction aims to provide liquidity benefits, with EUR shares being exchanged for a more liquid NASDAQ-listed CRML stock.
- The proposal includes consolidation of ownership interest in the Tanbreez Rare Earths project.
- The proposal is currently non-binding and subject to various conditions including due diligence and board recommendations.
- European Lithium’s Board has formed an independent committee to evaluate the proposal.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Proteomics International Laboratories Ltd (PIQ) ORDINARY FULLY PAID |
Health Care |
$26 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Apr 2026 9:13AM |
$0.265 |
$0.155 |
fallen by
41.51%
|
|
PIQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Strategic review completed and discontinuation of the DTC business model.
- Engagement with potential distribution partners in Australia and the USA.
- Continued validation and refinement of Promarker Endo and Promarker Eso assays.
- Organisational restructure resulting in cost savings exceeding $1 million.
- Leadership changes including the appointment of Mr David Morris as CEO and Managing Director.
- Cash outflows from operations totaled $2.6 million for the quarter ending 31 March 2026.
- Received $0.7 million from the exercise of PIQO options.
- Cash and cash equivalents stood at $5.7 million as of 31 March 2026.
- Net cash used in operating activities was $3.6 million year to date.
- Financial discipline and commercial strategy highlighted as a priority.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Victory Metals Limited (VTM) ORDINARY FULLY PAID |
Materials |
$196 |
72% Heavy Rare Earth ratio and a Second Zircon Hf Product
|
28 Apr 2026 9:13AM |
$1.750 |
$1.490 |
fallen by
14.86%
|
|
VTM - Price-sensitive ASX Announcement
Full Release
Key Points
- HREE/LREE separation achieved using Heavy Liquid Separation (HLS) technique
- 72% HREO:TREO ratio achieved in pre-concentrate testing
- High-grade HREE pre-concentrate identified in coarse fraction
- Potential non-Chinese supply chain for heavy rare earths and strategic metals
- Second Zircon Hafnium product identified in finer fractions
- Significant mineral resource estimates for the North Stanmore Project
- Potential for Scandium and Gallium as byproducts
- Ongoing focus on strategic defense metals production
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Regal Investment Fund (RF1) ORDINARY UNITS FULLY PAID |
Financials |
$753 |
Update - Notification of buy-back - RF1
|
28 Apr 2026 9:13AM |
$3.470 |
$3.620 |
risen by
4.32%
|
|
| PYC Therapeutics Limited (PYC) ORDINARY FULLY PAID |
Health Care |
$2,213 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
28 Apr 2026 9:12AM |
$1.310 |
$2.250 |
risen by
71.76%
|
|
PYC - Price-sensitive ASX Announcement
Full Release
Key Points
- PYC is progressing through Phase 1a/1b clinical studies for Polycystic Kidney Disease (PKD) and Autosomal Dominant Optic Atrophy (ADOA).
- The company reported enrolment and dosing advancements in its clinical trials, with plans for further studies in Q2 2026.
- PYC's financial position as of March 31, 2026, includes $667 million in cash and a $23 million R&D rebate.
- The company reported $16,666,000 in research and development expenses for the quarter.
- PYC is working on drug candidates for Retinitis Pigmentosa type 11 (RP11) and Phelan-McDermid Syndrome (PMS).
- The Appendix 4C cash flow report outlines a net cash use of $16,262,000 in operating activities for the quarter.
- PYC's financing activities brought in a net $563 million due to equity securities issuance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Pivotal Metals Limited (PVT) ORDINARY FULLY PAID |
Materials |
$18 |
Horden Lake Strategy Update
|
28 Apr 2026 9:11AM |
$0.015 |
$0.014 |
fallen by
6.67%
|
|
PVT - Price-sensitive ASX Announcement
Full Release
Key Points
- Mineral Resource update is in progress to enlarge the existing resource.
- A scoping study is advancing, targeting a large open-pit operation.
- Metallurgical testwork aims to improve recovery into clean concentrates.
- Horden Lake holds a strategic position with jurisdictional advantages in Québec.
- Resource growth potential with under-explored regional opportunities.
- The project is positioned against a backdrop of limited global copper development pipeline.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Call 1300 880 160
Start a chat
Schedule a call
